Remove Containment Remove Drug Delivery Remove Genomics
article thumbnail

Progenity Announces Pricing of Public Offering of Common Stock – Dec 03, 2020

The Pharma Data

The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Forward Looking Statements.

article thumbnail

Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering – Dec 03, 2020

The Pharma Data

The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Forward-Looking Statements.

Sales 40
article thumbnail

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Roots Analysis

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. mRNA drugs are considered to offer an effective alternative to gene therapies, specifically for protein replacement, as they avoid the risk of genome integration and offer strong transient expression.